Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Trial Details

NCT ID

NCT05079282

Phase

PHASE1

Sponsor

Ono Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

• ONO-4685

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Duarte, California, United States|34.13945,-117.97729
• Orange, California, United States|33.78779,-117.85311
• Palo Alto, California, United States|37.44188,-122.14302
• New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

• Patients aged ≥ 18 years at time of screening
• Written informed consent by the patient or the patients' legally authorized representative prior to screening
• Patients with histologically or cytologically confirmed diagnosis of one of the following subtypes of T-cell lymphoma:
• Peripheral T-cell lymphoma (PTCL): Angioimmunoblastic T-cell lymphoma (AITL), PTCL, not otherwise specified (PTCL-NOS), nodal PTCL with T-follicula…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.